Logo

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Share this
Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Shots:

  • The NMPA has approved a P-I/II SWATCH dose-escalation & dose-expansion study that evaluates the safety, tolerability, and preliminary efficacy of selinexor in combination with the R2 regimen of lenalidomide + rituximab for rrDLBCL and rriNHL who are not eligible for HDC or ASCT. The study was conducted at 10 centers across China
  • The 1EPs of the study are the MTD and RP2D as determined by the DLT observed in the dose-escalation phase along with other key safety measures. The 2EPs include ORR, PFS & DoR of the SR2 regimen as assessed acc. to the Lugano 2014 criteria (Cheson, 2014) for the assessment of lymphoma
  • Selinexor has already received the US FDA's approval for the treatment of rrDLBC

Ref: Antengene | Image: Antengene

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions